NPPA caps prices of 18 formulations packs including diabetes drugs
NPPA (National Pharmaceutical Pricing Authority) has recently put a cap on prices of 18 formulations packs. Under this recent development, the list of formulation packs covers anti- diabetic Metformin HCl tablets, antibacterial Ceftriaxone Sodium injection packs and devices, along with more drugs.
According to a press statement, the prices of the 18 formulation packs under consideration have either been fixed, or revised under Drug Price Control Order (DPCO), 2013, as stated by the National Pharmaceutical Pricing Authority.
Reporting further details, the prices have also been fixed/revised for hormone releasing IUD, ondansetron HCl orally disintegrating strip, Metformin HCl tablets, Cefaclass injection pack among others.
Under the new price action by the NPPA, firms such as Cipla, Alembic Pharma and Unichem Laboratories are likely to be impacted by the government's move for prices fixation and revision.
At present, the government caps prices of essential drugs based on the simple average of all medicines in a particular therapeutic segment with sales of more than 1%. In case of non scheduled formulations companies are allowed to hike prices of medicines by only up to 10% in a year. The government had notified DPCO 2013 to cover 680 formulations, effective May 15, 2014.
You get a copy of the circular at the link below
http://www.nppaindia.nic.in
According to a press statement, the prices of the 18 formulation packs under consideration have either been fixed, or revised under Drug Price Control Order (DPCO), 2013, as stated by the National Pharmaceutical Pricing Authority.
Reporting further details, the prices have also been fixed/revised for hormone releasing IUD, ondansetron HCl orally disintegrating strip, Metformin HCl tablets, Cefaclass injection pack among others.
Under the new price action by the NPPA, firms such as Cipla, Alembic Pharma and Unichem Laboratories are likely to be impacted by the government's move for prices fixation and revision.
At present, the government caps prices of essential drugs based on the simple average of all medicines in a particular therapeutic segment with sales of more than 1%. In case of non scheduled formulations companies are allowed to hike prices of medicines by only up to 10% in a year. The government had notified DPCO 2013 to cover 680 formulations, effective May 15, 2014.
You get a copy of the circular at the link below
http://www.nppaindia.nic.in
Next Story
